# OnCo record msi-high-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/msi-high-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "msi-high-pdac" ;
  schema:name "Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "MSI-high pancreatic cancer"@en, "dMMR pancreatic cancer"@en, "Mismatch repair deficient PDAC"@en, "Lynch syndrome-associated pancreatic cancer"@en ;
  schema:description "Mismatch repair deficient pancreatic cancer is the rare pancreatic cancer whose cells cannot fix spelling errors in DNA and so carry thousands of mutations. That makes it one of the few pancreatic cancers that immunotherapy works against, and pembrolizumab is approved for it, though fewer of these tumours respond than in bowel cancer; testing every pancreatic cancer for the defect is the point."@en ;
  schema:url <https://onco.cc/cancers/msi-high-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Microsatellite_instability> ;
  schema:citation <https://en.wikipedia.org/wiki/Microsatellite_instability>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/immune-desert-exclusion/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/germline-vs-somatic/> ;
  onco:trials <https://onco.cc/trials/keynote-177/> ;
  onco:people <https://onco.cc/people/dung-le/>, <https://onco.cc/people/bert-vogelstein/>, <https://onco.cc/people/elizabeth-jaffee/>, <https://onco.cc/people/eileen-oreilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/> ;
  onco:pipeline <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/technologies/shared-antigen-vaccine/>, <https://onco.cc/ideas/idea-prev-reflex-germline-testing/> ;
  onco:standardOfCare <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/> .